# RRAS2

Source: https://onco.cc/targets/rras2/  
OnCo record `rras2` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

RRAS2 (Ras-related protein R-Ras2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer, Ovarian cancer and Breast cancer.

## Summary

GTP-binding protein with GTPase activity, involved in the regulation of MAPK signalling pathway and thereby controlling multiple cellular processes. Regulates craniofacial development.

CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.76 (direct and indirect evidence; datatypes genetic literature 0.61, literature 0.93, genetic association 0.00, somatic mutation 0.88, animal model 0.30). IntOGen calls it a driver in 2 cohorts (2 activating, 0 loss-of-function), covering Endometrial Carcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: RAS related 2; Ras-related protein R-Ras2; TC21
- Tags: cancer-genes-wave
- Symbol: RRAS2
- Class: oncogene
- Biology: GTP-binding protein with GTPase activity, involved in the regulation of MAPK signalling pathway and thereby controlling multiple cellular processes. Regulates craniofacial development. Location: Cell membrane; Golgi apparatus membrane (UniProt). Locus 11p15.2 (HGNC).
- Where found: Endometrial cancer: Open Targets association 0.51 with endometrial cancer (MONDO_0011962); IntOGen driver in 2 cohorts (UCEC); Ovarian cancer: Open Targets association 0.58 with ovarian cancer (MONDO_0008170); Breast cancer: Open Targets association 0.52 with breast cancer (MONDO_0007254)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 2 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:17271: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17271
- UniProt P62070: https://www.uniprot.org/uniprotkb/P62070/entry
- NCBI Gene 22800: https://www.ncbi.nlm.nih.gov/gene/22800
- Ensembl ENSG00000133818: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000133818

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)

---
JSON: https://onco.cc/api/v1/entities/rras2.json